Immunomodulatory effects of statins: Mechanisms and potential impact on arteriosclerosis

Journal of the American Society of Nephrology

Volumn 13, Issue 6, 2002, Pages 1673-1681

  Palinski, Wulf ^a   Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; ARTERIOSCLEROSIS; ATHEROGENESIS; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL MODEL; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNE SYSTEM; IMMUNOMODULATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; ORGAN TRANSPLANTATION; OXIDATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH2 CELL; ANIMAL; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; LIPOPROTEINS, LDL;

EID: 0036014951     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000018400.39687.8C     Document Type: Review

References (106)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Statin therapy: Where are we? Where do we go next?
5. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management
6. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study. A randomized controlled trial
7. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention
8. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial
9. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
10. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
11. State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: Vascular protection beyond their primary mode of action
12. Current perspectives on statins
13. Direct vascular effects of HMG-CoA reductase inhibitors
14. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity
15. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2
16. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation
17. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
18. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages
19. HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation
20. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro
21. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae
22. Inhibition of monocyte chemotactic protein-1 synthesis by statins
23. Statins as a newly recognized type of immunomodulator
24. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site
25. Immunomodulation: A new role for statins?
26. Impact and management of hyperlipidemia post-transplantation
27. Effect of HMG-CoA reductase inhibitors on chronic allograft rejection
28. Regulation of the mevanolate pathway
29. Protein lipidation in cell signaling
30. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
31. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
32. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells
33. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
34. Acute modulation of endothelial Akt/PKB activity alters nitric oxide-dependent vasomotor activity in vivo
35. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
36. Nitric oxide as a signaling molecule in the vascular system
37. Novel effects of nitric oxide
38. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: An Overview
39. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture
40. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s)
41. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranylgeranylation and Rho proteins
42. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice
43. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species
44. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
45. Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production
46. Increased formation of distinct F2 isoprostanes in hypercholesterolemia
47. Oxygen radicals and signaling
48. Multiple role of reactive oxygen species in the arterial wall
49. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice
50. NF-kB: Pivotal mediator or innocent bystander in atherogenesis?
51. Oxidized LDL activates Fas-mediated endothelial cell apoptosis
52. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis
53. Apoptosis induced by mildly oxidized LDL involves multiple apoptotic signaling pathways in human coronary cells
54. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
55. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-gamma
56. Peroxysome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
57. A PPAR gamma-LXR-ABCA 1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
58. Are ACE inhibitors a "magic bullet" against oxidative stress?
59. The oxidative modification hypothesis of atherosclerosis: Does it hold for humans?
60. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A
61. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis
62. Low density lipoprotein undergoes oxidative modification in vivo
63. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein
64. Critical role for IL-4 in the development of transplant arteriosclerosis in the absence of CD40-CD 154 costimulation
65. CD8+ T cells contribute to the development of transplant arteriosclerosis despite CD 154 blockade
66. Immune mechanisms in atherosclerosis
67. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts
68. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice
69. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice
70. Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55
71. Reduction of atherosclerosis in mice by inhibition of CD40 signalling
72. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse
73. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65
74. Aherosclerosis, autoimmunity, and vascular-associated lymphoid tissue
75. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis
76. Immune deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet
77. T lymphocytes inhibit the vascular response to injury
78. Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity
79. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: Contribution to its anti-angiogenic effect
80. Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model
81. Effects of pravastatin on chronic rejection of rat cardiac allografts
82. Pravastatin increases survival and inhibits natural killer cell enhancement factor in liver transplanted rats
83. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts
84. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion
85. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin
86. Use of statins in CNS disorders
87. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
88. Simvastatin has anti-inflammatory and anti-atherosclerotic activities independent of plasma cholesterol-lowering
89. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum
90. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits
91. Lack of effect of lovastatin on restenosis after coronary angioplasty
92. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty: The PREDICT Trial Investigators. Prevention of Restenosis by Elisor After Transluminal Coronary Angioplasty
93. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial
94. Effect of pravastatin on outcomes after cardiac transplantation
95. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial
96. Long-term effects of pravastatin on plasma concentration of C-reactive protein
97. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels
98. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation
99. Effects of lovastatin on the immune system
100. Atorvastatin improves endothelial function in renal-transplant recipients
101. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation
102. The effect of pravastatin on acute rejection after kidney transplantation-a pilot study
103. Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial
104. The effects of lipid-lowering agents on acute renal allograft rejection
105. Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection
106. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data